AstraZeneca chief attacks Pfizer’s £63bn takeover bid
AstraZeneca's chief executive has launched a staunch attack on Pfizer’s £63bn takeover plan, saying it would jeopardise its “fragile” but ambitious drug discovery programme.
Pascal Soriot declared the company would grow annual sales to more than $45bn by 2023 from the current $25.7bn thanks largely to its pipeline of new medicines being developed. It was just that process of creating new drugs that would be jeopardised by a takeover, he said.
“I have been through enough mergers to known a company is not a machine. It is a group of people. If you disrupt their work you can really have a negative impact very quickly.”
AstraZeneca has gone from a position of having 57 drugs in 2012 to 84 now, as it has moved quickly to boost its development programme. Analysts say that, as well as the UK tax status, is what attracted Pfizer to make its bid.
Mr Soriot said: “Our people are very experienced, motivated and excited about what we are doing. We believe we can make an impact on medicine at this time. We have recruited very talented people. When you do this you really want to remain focused on the job at hand. "
He added: "Any distraction, any disruption, could have a negative impact on our ability to develop these products. A pipeline is something that is very fragile. That is why we believe we are better off focused on what we are doing.”
His view chimes with those of many scientists who have spoken out against the huge disruption a takeover of one of Britain’s two key pharmaceuticals champions could have.
Dr Scott Gottlieb, an adviser to pharmaceuticals companies and resident fellow at the American Enterprise Institute, said: “You get really fundamental product breakthroughs when you have small groups of scientists working together on new areas of science over a period of many years. When companies do these mergers, it can break up these teams and break up the continuity.”
Mr Soriot said AstraZeneca’s shareholders had been supportive so far, adding: "We are in a race with many of our competitors to bring our products to the marketplace as quickly as possible. Anything that creates disruption has the potential to destroy value."
He was speaking just hours after the chief executive of top 10 AstraZeneca shareholder Aberdeen Asset Management backed the Labour leader Ed Miliband’s calls for a public interest investigation into the deal.
Aberdeen chief executive Martin Gilbert told The Independent: “AstraZeneca’s management has done a good job refocusing the business and as far as we’re concerned remaining independent remains a viable outcome.
“We do have to look at this in UK terms because it is so important for our research and development. It’s got to be about more than tax benefits.”
Earlier, he told the BBC: “Pfizer unfortunately has this reputation of being ruthless cost-cutters.”
Mr Soriot added that speed of decisionmaking was critical to bringing new drugs to market – a fleetness of foot that could be disrupted by a massive merger.
However, he declined to get pulled into the increasingly tense political atmosphere around the deal, although he acknowledged that he had been asked to participate in MPs’ select committee hearings. Both the business and science committees yesterday confirmed they would be conducting meetings with the industry including representatives from both Pfizer and AstraZeneca.
- 1 Sabina Altynbekova, the girl branded 'too good looking' for volleyball, says social media obsession with her is a 'bit much'
- 2 Disney heiress Abigail disowns her share of family profits in West Bank company
- 3 The secret report that helps Israel hide facts
- 4 Israel's propaganda machine is finally starting to misfire
- 5 Zayn Malik on Israel-Gaza: One Direction singer bombarded with Twitter death threats after posting #FreePalestine
Sally Farmiloe dead: Howards' Way actress, and former mistress of Jeffrey Archer, dies aged 60
Sabina Altynbekova, the girl branded 'too good looking' for volleyball, says social media obsession with her is a 'bit much'
Disney heiress Abigail disowns her share of family profits in West Bank company
Australian model Robyn Lawley stages naked protest against huge coal mine seven times the size of Sydney Harbour
Drew Barrymore’s sister Jessica found dead in her car surrounded by 'dozens of white pills'
The secret report that helps Israel hide facts
Woman and two children killed by mob in riots over 'blasphemous' Facebook post in Pakistan
A day in the life of Vladimir Putin: The dictator in his labyrinth
Land for gas: Merkel and Putin discussed secret deal could end Ukraine crisis
Putin is 'thuggish, dishonest and reckless', says British ambassador to US
Richard Dawkins tweets: 'Date rape is bad, stranger rape is worse'
- < Previous
- Next >
iJobs Money & Business
£28000 - £32000 per annum: Ashdown Group: Secretary (Sales Team Support) - Mat...
£600 - £700 per day + competitive: Orgtel: Senior Investment Accounting Change...
£450 - £650 per day + competitive: Orgtel: My client, a leading bank, is curre...
£350 - £400 per day + competitive: Orgtel: Senior Analyst, ALM Data, Halifax, ...